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Abstract
Cell tracking with magnetic resonance imaging (MRI) and iron nanoparticles is commonly used to monitor the fate
of implanted cells in preclinical disease models. Few studies have employed these methods to study cancer cells
because proliferative iron-labeled cancer cells will lose the label as they divide. In this study, we evaluate the po-
tential for retention of the iron nanoparticle label, and resulting MRI signal, to serve as a marker for slowly dividing
cancer cells. Green fluorescent protein–transfected MDA-MB-231 breast cancer cells were labeled with red fluo-
rescent micron-sized superparamagnetic iron oxide (MPIO) nanoparticles. Cells were examined in vitro at multiple
time points after labeling by staining for iron-labeled cells and by flow cytometric detection of the fluorescent
MPIO. Severe combined immune deficiency (SCID) mice were implanted with 5 × 105 MPIO-labeled or unlabeled
cells in the mammary fat pad and MRI was performed weekly until 28 days after injection. Microscopy was per-
formed to validate MRI. In vitro assays revealed a very small percentage of cells that retained MPIO at 14 days after
labeling. Regions of signal loss were observed in MRI of primary tumors that developed from iron-labeled cancer
cells. Small focal regions of signal loss were detected in images of the axillary and brachial nodes in six of eight
mice, at day 14 or later, with microscopy confirming the presence of iron-labeled cancer cells. Our data suggest an
interesting role for cell tracking with iron particles since label retention leads to persistent signal void, allowing
proliferative status to be determined.
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Introduction
Magnetic resonance imaging (MRI) is a commonly used imaging
method for tracking cells in vivo in preclinical models of disease. To
accomplish this, cells are labeled with a contrast agent before their
injection or transplantation. Most cell tracking studies have used super-
paramagnetic iron oxide (SPIO) nanoparticles for cell labeling. SPIO
particles disturb the static magnetic field, and this effect extends well
beyond the volume of the cell, resulting in a dramatic reduction in
the T2 and T2* of nearby water molecules. T2- and T2*-based imaging
methods depict SPIO-labeled cells as pronounced local signal voids or
hypointense regions [1]. A variety of cell types has been studied using
this approach. Examples include monitoring the fate of transplanted
stem/progenitor cells in myocardial infarction [2,3], stroke [4], spinal
cord injury [5,6], and multiple sclerosis [7] and detecting the migration
of dendritic cells used in cancer immunotherapy [8–10]. While most
studies focus on the visualization of relatively large numbers of cells,
even single iron-labeled cells can be detected in vivo by MRI [11,12].
Few groups have used iron nanoparticles and MRI to track cancer
cells. This is primarily because the SPIO label is diluted over time in
dividing cells leading to loss of signal and therefore loss of cell detection
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[13]. However, we and others have shown that the retention of iron
particles in nonproliferative, or slowly cycling, cancer cells can be
exploited to detect particular cancer cell populations [14–16]. Heyn
et al. demonstrated that a small percentage of brain metastatic human
breast cancer cells arrest in the mouse brain and persist as distinct signal
voids in a nonproliferative state, while another population of cancer
cells proliferate and form brain metastases [14]. Townson et al. injected
iron-labeled metastatic melanoma cells into the mouse liver and used
MRI to show that cytotoxic chemotherapy with doxorubicin reduced
liver tumor burden but did not affect the number of nonproliferative
cancer cells [15]. Iron-retaining cancer cells have also been observed by
MRI in melanoma xenografts implanted subcutaneously in mice [16];
Magnitsky et al. demonstrated that a small, distinct subpopulation of
iron-retaining cells could be detected by flow cytometry after 20 days
of in vitro proliferation [16]. These papers all demonstrated the ability
to use iron nanoparticles and MRI to image cells with a slow prolifera-
tion phenotype.
The cells these papers are targeting have been referred to as non-
proliferative, quiescent, slowly cycling, or dormant. Despite the diverse
nomenclature, the common goal of these studies has been to character-
ize a subpopulation of cancer cells that is believed to play a critical role
in tumor progression and metastasis. Several experimental metastasis
models, using a variety of cancer cell lines, show the presence of non-
proliferative cancer cells, often coexisting in a metastatic site with actively
growing metastases [17–19]. In breast cancer, metastatic cancer cells
can sometimes remain dormant for decades until some poorly under-
stood trigger causes them to proliferate and progress to clinically relevant
metastases [20].
In this paper, we use this concept of label retention to examine
this subpopulation of cancer cells in a murine model of breast cancer
metastasis. We investigate the distribution of nonproliferative cancer
cells within the primary tumor and the migration of these cells to
distant lymph nodes.
Materials and Methods
Cell Culture and In Vitro Experiments
A green fluorescent protein (GFP) expressing transformant of the
human breast cancer cell line MDA-MB-231 (231) was used. Cells
were labeled with Flash Red fluorescent micron-sized superpara-
magnetic iron oxide (MPIO) particles (excitation: 660, emission: 690;
Bangs Laboratories Inc, Fishers, IN). Briefly, 106 cells were plated onto
T75 flasks with normal complete medium. After 24 hours, the medium
was replaced with a labeling medium containing MPIO particles at a
concentration of 0.049 mg Fe/ml and cells were incubated for another
24 hours before being harvested.
To determine how MPIO particles diluted with proliferation, the
cells were harvested on days 1, 2, 4, 7, 10, and 14 after addition of
the labeling medium (n = 3 flasks per time point). A cell sample was
taken from each flask at all time points, centrifuged onto microscopy
slides, and stained for iron with Perls’ Prussian Blue (PPB). The num-
ber of iron-labeled cells and the total number of cells were counted in
five different fields of view from each sample and the percentage of
labeled cells was determined for each time point.
This experiment was repeated and analyzed using flow cytometry.
We collected cell samples at days 1, 2, 4, 7, 10, and 14 (n = 3 flasks
per time point). All analyses were performed using an LSR II flow
cytometer (Becton Dickinson, Mississauga, Ontario). The fluorescence
signal of the MPIO particles’ Flash Red label was obtained by excita-
tion with a 640-nm laser and detected using a 670/30 filter, and 2 ×
105 events were acquired. The iron content of cells at each time point
was assessed by examining the amount of fluorescence of the MPIO
particles in each sample. A sample of unlabeled 231 cells was also col-
lected for use as a control.
Animal Model
Unlabeled (n = 8) or MPIO-labeled (n = 8) GFP-positive 231 cells
(5 × 105) were injected into the right thoracic mammary fat pad of
female CB-17 severe combined immune deficiency (SCID; CB17/
Icr-Prkdcscid/IcrIcoCrl) mice aged 6 to 8 weeks (Charles River Lab-
oratories, Wilmington, MA). Animals were imaged using MRI on
days 0, 7, 14, 21, and 28 after the cell injection. Mice were sacrificed
either after the appearance of signal loss in MR images of either the
ipsilateral axillary or brachial lymph nodes (five of eight mice in
labeled group) or on day 28 after all imaging had been completed.
MRI Methods
All imaging sessions were conducted using a 1.5-T CV/I MRI scan-
ner (General Electric Medical Systems, Milwaukee, WI) along with a
custom-built gradient coil insert (inner diameter = 17.5 cm, maximum
gradient strength = 500 mT/m, and peak slew rate = 3000 T/m/s) and
a custom-built solenoid mouse body radio-frequency coil (4 cm in
length and 3 cm in diameter). All images were acquired with a three-
dimensional balanced steady-state free precession (bSSFP) pulse
sequence. The bSSFP sequence was chosen because it provides very
high signal-to-noise ratio efficiency, allowing for high-resolution image
acquisitions of the whole mouse body in reasonable scan times, and
because it produces very good soft tissue contrast, related to T2/T1.
The scan parameters for bSSFP were given as follows: repetition time =
6.7 milliseconds, echo time = 3.3 milliseconds, flip angle = 40°, band-
width = ±31.25 kHz, matrix = 300 × 300, field of view = 6 cm,
0.2-mm slice thickness, 200-μm isotropic spatial resolution, four signal
averages, four radio-frequency phase cycles, and scan time of 34 minutes.
Microscopy Methods
The left and right axillary and brachial lymph nodes and the pri-
mary tumors were removed from the animals at necropsy. The tissues
were then placed in 3.75% formaldehyde in 0.1 M phosphate buffer
overnight to fix the tissue. Some lymph nodes and tumors were then
paraffin embedded for PPB staining and others were placed in a
sucrose gradient over the next 3 days, followed by embedding in
OCT compound for cryosectioning for fluorescencemicroscopy. Tissue
samples were cut into 5-μm sections for paraffin-embedded samples
and 16 μm for frozen samples. For fluorescence microscopy, frozen
lymph node sections were thawed and stained with 4′,6-diamidino-2-
phenylindole (DAPI) for cell nuclei. PPB staining was performed on
both frozen and paraffin-embedded sections. All microscopy was
performed on a Zeiss AXIO Imager (Carl Zeiss Canada Ltd, Toronto,
Ontario). Fluorescence images were taken using GFP, Texas Red,
and DAPI filters. Confocal fluorescence images were acquired on a
Fluoview FV10i confocal microscope (Olympus Canada Inc, Richmond
Hill, Ontario) using a 473-nm laser for GFP and a 635-nm laser for
Cy5.5 excitation.
Image Analysis
The volume of the tumors and the left and right axillary and brachial
lymph nodes were measured by manual segmentation using the OsiriX
image analysis software [21]. The axillary and brachial lymph nodes
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were chosen for analysis because these nodes are primarily responsible
for draining the area of the mammary fat pad where the cells were in-
jected. The OsiriX image analysis software [21] was used to make all
measurements from the images acquired in this study. Each tumor or
lymph node was segmented individually on every image slice to create a
series of regions of interest. The volume was then calculated by using
the region-of-interest volume calculation tool available within the soft-
ware package.
Tumor maps that distinguished between low signal intensities
generated from iron oxide particles (blue-colored zone), intermediate
signal intensities associated with tumor parenchyma (green-colored
zone), and high signal intensities related to fluid within the tumor
(yellow-colored zone) were created. The image analysis program
ImageJ [22] was used to generate the cutoff values for the low and
high signal intensities.
Images of single PPB-stained sections were compared with com-
posite images of six individual images of PPB-stained sections that
were merged using the Adobe Photoshop Elements 8 software pack-
age (Adobe Systems Incorporated, San Jose, CA). Briefly, six images
of consecutive PPB-stained tissue sections were overlaid and aligned.
Areas of positive staining were outlined in each section and a new
image layer was created from the outlined areas, colored blue, and
made visible above one image of the PPB-stained tissue sections.
All statistical analyses were done using the GraphPad Prism soft-
ware (GraphPad Software, Inc, La Jolla, CA). Data were analyzed
using the repeated measures analysis of variance test, the Student’s
t test, and the nonparametric Mann-Whitney test. P values were
considered significant if they were less than .05.
Results
In Vitro Iron Dilution
231 cells were labeled in vitro with MPIO particles and their iron
content was assessed at days 1, 2, 4, 7, 10, and 14 after labeling by
counting PPB+ cells in stained cell samples or bymeasuring the amount
of red fluorescence associated with the MPIO using flow cytometry.
Cell viability after labeling (day 1 time point) was 99.2 ± 0.6%. Figure 1
shows the PPB-stained cell samples along with the quantification of the
percentage of PPB-positive–labeled cells detected at each time point.
As the cells divided, the numbers of cells that contained iron particles
decreased. At days 1 and 2 after labeling, 99.0 ± 0.3% and 86.0 ± 1.4%
of cells were labeled. The number of labeled cells decreased to 43.1 ±
1.6% at day 4, 7.6 ± 1.6% at day 7, 1.0 ± 0.3% at day 10, and 0.8 ±
0.3% at day 14.
Similar results were observed when cells were analyzed using flow
cytometry. Figure 2A shows the percentage of iron-labeled cells, based
on the red fluorescence associated with MPIO, at each time point. At
days 1 and 2 after labeling, 99.9 ± 0.1% and 97.0 ± 0.1% of cells were
positive for the red fluorescent particles. The number of labeled cells
decreased to 45.7 ± 1.4% at day 4, 9.5 ± 0.9% at day 7, 2.6 ± 0.9%
at day 10, and 0.5 ± 0.1% at day 14. Figure 2B shows representative
dot plots of the flow cytometry data collected for each time point. The
plots display the fluorescence of the particles in the red channel on the
x-axis and side scatter on the y-axis. Although the iron content diluted
as cells proliferated, iron-labeled cells could still be detected at 14 days
after labeling.
MRI of Primary Tumor
Images of iron-labeled tumors (Figure 3A) had large, obvious areas of
signal loss within the developing mass. At day 14, developing tumors
appeared with mainly low signal intensity throughout. At day 21, the
MRI of tumors showed regions of low signal along with regions of
mixed, heterogeneous signal intensities. Images acquired on day 28
show that as the tumors became larger the regions of signal loss per-
sisted and more of the tumor mass appeared with intermediate/high
signal intensities. The images of tumors that developed from unlabeled
231 cells (Figure 3B) had a different MRI appearance. These tumors
had a homogeneous, intermediate signal intensity at day 14 and became
more heterogeneous in signal as the tumors grew in size. However,
regions of hypointensity, such as observed in images of the iron-labeled
tumors, were not observed in unlabeled tumors.
Tumor color maps are shown together with the MRI to assist with
visualization of the tumor borders and to highlight the three zones of
signal intensities observed. Blue represents the regions of signal hypo-
intensity (due to iron particles), yellow represents regions of hyper-
intense signal (most likely due to fluid/necrosis), and green represents
Figure 1. Stained cell samples of MPIO-labeled MDA-MB-231 cells at 1, 4, 7, 10, and 14 days after labeling. Graph of percentage of
iron-labeled MDA-MB-231 cells over time.
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Figure 2. In vitro dilution of MPIO particles in MDA-MB-231 cells measured by flow cytometry. (A) Graph of percentage of iron-labeled
MDA-MB-231 cells over time. (B) Plots of Flash Red fluorescence intensity (x-axis) versus side scatter (y-axis) at days 1, 2, 4, 7, 10, and
14 with gates shown for the labeled population (based on unlabeled control sample).
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the intermediate signal intensities (the bulk of the tumor mass). There
is a distinct difference in the color maps for labeled (Figure 3A) and un-
labeled tumors (Figure 3B). The percentage of the total tumor volume
within each of the three zones was measured for all tumors and is shown
in Table 1. For iron-labeled tumors, 91.4% of the tumor volume was
composed of the low signal intensity zone (blue in color map) at the first
imaging time point (day 7) and this decreased to 4.6% at the last im-
aging time point (day 28). In comparison, 1% or less of the volume of
unlabeled tumors fell within this zone at any time point. The percentage
of the tumor volume within the low signal intensity zone was com-
pared between labeled and unlabeled groups at each time point using
a Mann-Whitney test. Significant differences were found at all times
(day 7, P = .004; day 14, P = .0007; day 21, P = .0095; day 28, P =
.0238). There was no significant difference in total tumor volume be-
tween the iron-labeled and unlabeled tumors at any imaging time point.
Histology of Primary Tumor
Tumors were sectioned and stained for iron with PPB. Figure 4
depicts a tumor generated from MPIO-labeled 231 cells at day 14 after
injection. Figure 4, A, D, and F , shows a single 16-μm PPB-stained
section of the tumor at increasing magnification. These sections show
the presence of iron-labeled cells within the tumor. Figure 4, B and E ,
shows merged images of six consecutive PPB-stained sections showing
the summed iron content of all six sections. The data are presented
this way to illustrate the conundrum of comparing 16-μm stained tis-
sue sections with 200-μm MRI slices. A total of 12 tissue sections
like these would have to be merged perfectly for a true representation
of the extent of iron-labeled cells contained in the image slice. Over-
all, all tumors contained iron-labeled cells distributed throughout the
tumor mass.
Detection of Regions of Signal Loss in Lymph Nodes
Of particular interest was the observation of regions of signal loss
in images of the draining lymph nodes, in six of eight mice that re-
ceived MPIO-labeled 231 cells. Figure 5, A (arrow), B, and C , shows
a representative image of an ipsilateral axillary lymph node at day 14
with a focal region of signal loss and the corresponding PPB-stained
sections, respectively. The MRI and histology showed good corre-
spondence. In this example, signal loss was observed on one side of
the node and the most intense PPB staining was located in the same
location. Fluorescence microscopy was used to validate the presence
of MPIO+ cancer cells within nodes.
In Figure 6, A to D, an ipsilateral axillary node that showed a region
of signal loss at day 28 was found to contain GFP+ cells and regions
of red fluorescence that were co-localized, indicating the presence of
iron-labeled cancer cells in the node. Confocal microscopy was also
performed on some lymph nodes (Figure 7). Tissue sections were im-
aged with GFP and Cy5.5 fluorescence. Confocal image overlays of an
ipsilateral axillary lymph node at 28 days after the 231 cell injection
clearly show the presence of a number of GFP+ cells, which contain
red fluorescent particles, located in the node. These data also indicate
that the cancer cells have retained the MPIO label after migrating from
the tumor to the node.
Fluorescence microscopy images of the lymph node sections also re-
vealed that areas of green and red fluorescence did not always overlap.
Occasionally, red fluorescent areas that correlated with DAPI staining
for cell nuclei but not with areas of green fluorescence were found (data
not shown). This suggests that the red fluorescent iron particles can be
found in other cell types within the lymph node and may represent
bystander cell uptake of iron associated with dead tumor cells.
Tables 2 and 3 summarize the analysis of axillary and brachial lymph
nodes that were examined with both MRI and microscopy. The time
point that each node was examined at is also included in these tables.
Table 2 shows that five of six axillary lymph nodes were positive for
signal loss in MR images and that the presence of iron-labeled cells
was confirmed for all five nodes, with either PPB staining or fluo-
rescence microscopy. One axillary node did not have signal loss within
it (was MRI negative); however, fluorescence microscopy revealed cells
in the node that were both GFP and red MPIO positive. The sensi-
tivity of detection of signal loss by MRI due to iron-labeled cells in
the axillary nodes was therefore 83%.
Table 3 shows that two of five brachial lymph nodes were posi-
tive for signal loss on MRI; iron-labeled cells were detected by PPB
Figure 3. Appearance of labeled and unlabeled tumors over time
and corresponding tumor color maps. (A) The MR image and color
map, respectively, of a labeled tumor over time. (B) The MR image
and color map, respectively, of an unlabeled tumor. For color maps,
blue represents below low intensity cutoff (day 7, 255; day 14, 288;
day 21, 301; day 28, 320), green represents between low intensity
cutoff and high intensity cutoff (signal intensities of 700), and yellow
represents above high intensity cutoff.
Table 1. Tumor Volume and Percentage of Tumor Volume in Tumor Color Map Zones.
Percentage in Blue Zone Percentage in Green Zone Percentage in Yellow Zone Tumor Volume (mm3)
Labeled Tumors Unlabeled Tumors Labeled Tumors Unlabeled Tumors Labeled Tumors Unlabeled Tumors Labeled Tumors Unlabeled Tumors
Day 7 91.4 ± 15.0 0.5 ± 0.4 7.8 ± 13.1 98.2 ± 1.0 0.8 ± 1.9 1.3 ± 0.9 16.3 ± 7.3 10.2 ± 4.7
Day 14 81.4 ± 6.8 0.4 ± 0.5 17.5 ± 6.1 98.5 ± 0.6 1.2 ± 1.1 1.0 ± 0.8 169.9 ± 81.9 158.5 ± 90.4
Day 21 12.1 ± 6.1 0.1 ± 0.05 85.2 ± 6.6 88.7 ± 7.0 2.7 ± 0.8 11.4 ± 7.0 839.9 ± 496.2 1003.7 ± 443.5
Day 28 3.4 ± 2.4 0.1 ± 0.02 87.7 ± 7.5 85.2 ± 5.1 9.0 ± 5.1 14.8 ± 5.1 1994.5 ± 661.1 2574.7 ± 891.0
The blue zone is below low intensity cutoff (signal intensity of 255), the green zone is between low intensity cutoff and high intensity cutoff (signal intensity of 700), and the yellow zone is above high
intensity cutoff.
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staining in both of these nodes. For three brachial lymph nodes, no
signal loss was detected by MRI even though the fluorescence micros-
copy for all three of these nodes showed cells that were both GFP and
red MPIO positive. The sensitivity of detection of signal loss by MRI
due to iron-labeled cells in the brachial lymph node was only 40%.
Discussion
The goal of this study was to investigate the potential for tracking
metastatic cancer cells using iron oxide nanoparticles and MRI. We
have demonstrated that the retention of iron particles in some cancer
cells allows for their long-term tracking in vivo. Previously, we studied
the fate of iron-labeled cancer cells in a model of breast cancer metas-
tasis to the brain [14] and in a model of melanoma metastasis in the
liver [15]. In those models, cancer cells were delivered to the organ
of interest (brain or liver) by systemic injection (intracardiac left ven-
tricle or intrahepatic vein) to mimic the hematogenous spread of meta-
static cancer cells. In the current study, we have used an orthotopic
model of breast cancer and have examined the draining lymph nodes
for metastasis.
Cell tracking with MRI and magnetic nanoparticles has not been
widely applied to study cancer cells because the iron label is diluted
during cell division. Since the detection of iron-labeled cells by MRI
relies on the total iron content, this means that eventually the cancer
cells will not contain enough iron to be detected as signal voids in MR
images. Early in vitro studies by Arbab et al. showed that mesenchymal
stem cells, which are slowly dividing cells in culture, retained SPIO
particles for up to 7 weeks after cell labeling, whereas iron-labeled
cancer cells (HeLa) lost their iron label by 2 to 3 weeks after cell label-
ing [23]. We have previously reported the dilution of SPIO in fast
Figure 4. PPB-stained section of labeled tumor at day 14. (A) PPB-stained section of tumor lobe. (B) PPB-stained section showing the
iron content from six consecutive sections (blue areas). (C) MR image of tumor. (D) PPB-stained section of tumor from area outlined by
box in A. (E) PPB-stained section showing the iron content from six consecutive sections (blue areas), from area outlined by box in B.
(F) PPB-stained section of tumor from area outlined by box in D.
Figure 5. MRI and iron staining of an ipsilateral axillary lymph node
14 days after iron-labeled breast cancer cells were implanted into
the thoracic mammary fat pad in CB17 SCID mice. (A) Cropped
bSSFP image of thorax region of mouse reveals a region of signal
loss in the ipsilateral axillary node (arrow). (B) Section of lymph node
stained with PPB for iron detection at ×10 magnification shows
iron-positive cells in the area of the node corresponding to the sig-
nal loss in the MR image (arrow). (C) Iron-positive area of the node
at ×40 magnification, where strong staining can be seen (arrow)
suggesting that cancer cells have retained iron particles after migrat-
ing to the node.
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growing mouse melanoma (B16F10) cancer cells to below MR detect-
able levels in only 4 to 5 days after cell labeling [24]. In the current
study, both the analysis of PPB-stained cells in stained cell samples
and the flow cytometric analysis showed that in vitro by day 4 after
cell labeling the number of MPIO-labeled 231 cells was under 50%
and that this declined to less than 5% at day 10 after labeling. Still,
at 14 days (∼14 cell divisions) after labeling, a very small proportion
of the cancer cells retained the iron label. This finding is in agreement
with a study by Magnitsky et al. who detected a small population of
MPIO-retaining human melanoma cells (∼1%) at day 20 after cell
labeling (∼17 cell divisions). They also used demonstrated a correlation
between iron-retaining cells and expression of JARID1B, a biologic
marker of slow cycling cells [16].
Our in vivo MRI data also show that not all cancer cells lose the
iron label over time, indicating that not all cancer cells undergo
extensive proliferation. This is perhaps expected since solid tumors
are known to have pronounced heterogeneity, with different sub-
populations of cancer cells (and normal stromal cells) co-existing.
The list of characteristics by which these subpopulations differ is ex-
tensive but includes cellular morphology, receptors, enzymes, growth
rates, and gene expression to name a few [25]. Marked differences
in the proliferation behavior of tumor cells within a single cancer are
typical [25]. Some cells are nonproliferative and others are cycling,
but this can occur at various rates, and at any given time, cycling cells
within the tumor will be at different stages of the cell cycle.
MRI of the primary mammary fat pad tumors showed that the
iron-labeled cells (blue zone) encompass the whole tumor in the first
2 weeks and then, as the tumor volume increases, make up less of the
tumor mass and appear to remain located together in one region of
the tumor. Because sister cells have been shown to remain contiguous
in solid tumors, sublines tend to be localized regionally or zoned [26–
28]. Therefore, the zone of iron-retaining cells within these tumors
may reflect the presence of a specific subpopulation.
The ability to detect iron-labeled 231 cells in the ipsilateral axillary
and brachial lymph nodes after implantation of these cells in the mam-
mary fat pad is intriguing. Because we rarely observed GFP+ cancer
cells in the nodes that were not also red fluorescent, our data suggest
that there may be a relationship between the iron-retaining cell popu-
lation and an invasive or metastatic phenotype. This is the first paper
to demonstrate the migration of iron-labeled cancer cells from a pri-
mary tumor using MRI. The sensitivity of detecting signal loss by
Figure 6. MRI and fluorescence microscopy of a representative
SCID mouse ipsilateral axillary lymph node 28 days after tumor cell
implantation. CB17 SCID mice were injected with GFP-positive
MDA-MB-231 cells labeled with red fluorescent iron oxide particles.
(A) Cropped bSSFP MRI image of the ipsilateral axillary lymph node
shows a region of signal loss within the node (arrowhead). (B) GFP-
positive cancer cells found within node correspond with (C) red
fluorescent MPIO particles. (D) Overlay of GFP fluorescent cells,
red fluorescent MPIO, and DAPI stain for cell nuclei. Cells that are
positive for both GFP and contain red fluorescent particles can
be found within the node, confirming the presence of iron-labeled
cancer cells.
Figure 7. Confocal microscopy image of MPIO-labeled MDA-MB-
231 cells in an ipsilateral axillary lymph node 28 days after tumor cell
implantation. (A) Image at ×60 magnification. Area in white box has
been enlarged (B) to show the localization of MPIO particles (red)
in the cells (green).
Table 2. Analysis of Axillary Lymph Nodes Examined with Both MRI and Either PPB Staining or
Fluorescence Microscopy.
Axillary Lymph Node Signal Loss in
MR Images
Positive in Microscopy
(Positive PPB Staining or GFP
and Red MPIO-Positive Cells)
Time Point Removed
1 Yes Yes, PPB Day 14
2 Yes Yes, PPB Day 14
3 Yes Yes, FL Day 14
4 Yes Yes, FL Day 21
5 No Yes, FL Day 14
6 Yes Yes, FL Day 28
FL indicates fluorescence microscopy.
Table 3. Analysis of Brachial Lymph Nodes Examined with Both MRI and Either PPB Staining or
Fluorescence Microscopy.
Brachial Lymph Node Signal Loss in
MR Images
Positive in Microscopy
(Positive PPB Staining or GFP
and Red MPIO-Positive Cells)
Time Point Removed
1 Yes Yes, PPB Day 14
2 Yes Yes, PPB Day 14
3 No Yes, FL Day 14
4 No Yes, FL Day 21
5 No Yes, FL Day 28
FL indicates fluorescence microscopy.
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MRI due to the presence of iron-labeled cancer cells was found to be
83% for the axillary node and 40% for the brachial node. This is likely
because the axillary nodes in the mouse are easier to visualize in the
MR images than the brachial nodes because the axillary node sits in a
more prominent fat pad that generates very good image contrast in
bSSFP images (fat is bright; node tissue is intermediate).
Our data suggest that nonproliferative, or slowly cycling, cancer cells
can be detected by in vivo MRI. Nonproliferative cancer cells, some-
times referred to as dormant cells, are believed to contribute to tumor
recurrence. Clinical dormancy is reflected by relapses at distant sites
after the original primary cancer diagnosis. In some tumors, for exam-
ple, breast cancer, melanoma, and renal cancer, these recurrences are
common and can occur many years after diagnosis [29]. Dormant
cancer cells also present a substantial therapeutic problem; because they
are quiescent, they are nonresponsive to current therapies that target
proliferating cells [16–18]. Discerning the mechanisms that either
maintain prolonged cellular dormancy or activate dormant tumor cells
to a proliferative state has been a recognized goal of scientists world-
wide. Still, relatively little is known about dormant cancer cells and
studying these cells is challenging since, at the present time, there are
no suitable in vivo assays. It is exciting to consider that advanced in vivo
cellular imaging techniques, as described in this paper, may be used to
study the fate of distinct subpopulations of metastatic breast cancer
cells within the whole tumor in the intact mouse body.
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